• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Study supports Acusphere agent

Article

A study presented at last month’s American College of Cardiology meeting indicates that an ultrasound contrast agent under development by Acusphere of Cambridge, MA, could be used in a continuous mode. Imaging continuously with AI-700 could

A study presented at last month’s American College of Cardiology meeting indicates that an ultrasound contrast agent under development by Acusphere of Cambridge, MA, could be used in a continuous mode. Imaging continuously with AI-700 could help clinicians overcome some of the shortcomings of other agents, which have short persistence times because their contrast-enhancing microbubbles break up under ultrasound beams. Acusphere believes that the AI-700 microbubbles may have longer persistence times because they are made from synthetic polymers. AI-700 is in phase I clinical trials.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.